Isomorphic Labs, an Alphabet AI drug development unit, is reportedly in talks to raise over $2 billion in its first major funding round. Thrive Capital, an existing investor, is expected to lead the round, which aims to accelerate the company's AI-driven drug discovery pipeline. The substantial investment underscores significant investor confidence in Isomorphic Labs' approach to revolutionizing pharmaceutical research.
Amount: $2.0B
